A Look at Medtronic’s Recent Stock Performance
Medtronic (MDT) was trading at $83.9 on May 22, 2017. It had a 50-day moving average of $82.1 and a 200-day moving average of $78.4.
In a Reuters survey of 25 brokerage companies on May 22, 2017, ~56% of analysts rated Medtronic as a “buy,” and 44% rated it as a “hold.”
Medtronic accounts for ~1.1% of the total holdings of the iShares Russell 1000 Value ETF. The company has consistently reported higher earnings than analysts’ earnings estimates.
Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.9 billion in fiscal 4Q17, a rise of ~4% compared to its fiscal 4Q16 revenue of $7.6 billion.
Medtronic, one of the leading healthcare companies in the United States, plans to release its fiscal 4Q17 results on May 25, 2017.
BDX stock’s consensus 12-month target price is $189.89, which implies a ~3.1% return potential as compared to BD’s price of $184.13 on May 19.
BD (BDX) expects its 2017 revenues to witness a YoY (year-over-year) rise of 4.5%–5% on a comparable currency-neutral basis.
On May 19, BD was trading at $184.13, as compared to its 50-day moving average of $183.37 and its 200-day moving average of $176.94.
For fiscal 2Q17, Becton, Dickinson, and Company (BDX), or BD, reported a 90-basis-point improvement in its gross margin.
In its diabetes business, BD (BDX) is working with Medtronic (MDT) to relaunch a new infusion set, after the temporary suspension of its shipments.
In 1Q17, Bio-Rad Laboratories’ (BIO) Life Science segment reported revenues of ~$174.3 million, which represents a YoY rise of ~5.1%.
On March 13, 2017, Bio-Rad Laboratories (BIO) announced that it expects to reach an EBITDA margin of around 20% by 2020.
On March 13, 2017, Bio-Rad Laboratories (BIO) provided a long-term, currency-neutral revenue growth target of around 3%–5%.
In 1Q17, Bio-Rad Laboratories (BIO) reported revenues of ~$500.1 million, which represented a YoY (year-over-year) rise of around 6.1%.
BD has accelerated its plans to shift from a product-centric to customer-centric end-to-end solutions provider through various collaborations and partnerships.
On May 2, 2017, BD registered adjusted diluted EPS of $2.30 for fiscal 2Q17, which represents ~12.8% YoY (year-over-year) growth.
As part of Obamacare, a medical device tax of 2.3% has been implemented on medical device companies in the United States.
President Donald Trump’s proposed policies were expected to boost US economic growth and revive the country’s employment outlook. However, investors are starting to grow wary.
Dentsply Sirona (XRAY) released its 1Q17 results on May 9, 2017. Let’s take a look at Wall Street analysts’ recommendations and target prices for XRAY over the next year.
Dentsply Sirona (XRAY) expects its 2017 constant currency revenue to witness a YoY (year-over-year) rise of 4%–6%, in line with its previous guidance.